21 results on '"Suzanne Jurriaans"'
Search Results
2. Differences in SARS-CoV-2 infections during the first and second wave of SARS-CoV-2 between six ethnic groups in Amsterdam, the Netherlands: A population-based longitudinal serological study
- Author
-
Liza Coyer, Anders Boyd, Janke Schinkel, Charles Agyemang, Henrike Galenkamp, Anitra D.M. Koopman, Tjalling Leenstra, Yvonne T.H.P. van Duijnhoven, Eric P. Moll van Charante, Bert-Jan H. van den Born, Anja Lok, Arnoud Verhoeff, Aeilko H. Zwinderman, Suzanne Jurriaans, Karien Stronks, and Maria Prins
- Subjects
SARS-CoV-2 ,COVID-19 ,Infection ,Incidence ,Serology ,Antibody ,Public aspects of medicine ,RA1-1270 - Abstract
Summary: Background: Surveillance data in high-income countries have reported more frequent SARS-CoV-2 diagnoses in ethnic minority groups. We examined the cumulative incidence of SARS-CoV-2 and its determinants in six ethnic groups in Amsterdam, the Netherlands. Methods: We analysed participants enrolled in the population-based HELIUS cohort, who were tested for SARS-CoV-2-specific antibodies and answered COVID-19-related questions between June 24-October 9, 2020 (after the first wave) and November 23, 2020-March 31, 2021 (during the second wave). We modelled SARS-CoV-2 incidence from January 1, 2020-March 31, 2021 using Markov models adjusted for age and sex. We compared incidence between ethnic groups over time and identified determinants of incident infection within ethnic groups. Findings: 2,497 participants were tested after the first wave; 2,083 (83·4%) were tested during the second wave. Median age at first visit was 54 years (interquartile range=44–61); 56·6% were female. Compared to Dutch-origin participants (15·9%), cumulative SARS-CoV-2 incidence was higher in participants of South-Asian Surinamese (25·0%; adjusted hazard ratio [aHR]=1·66; 95%CI=1·16–2·40), African Surinamese (28·9%, aHR=1·97; 95%CI=1·37–2·83), Turkish (37·0%; aHR=2·67; 95%CI=1·89–3·78), Moroccan (41·9%; aHR=3·13; 95%CI=2·22–4·42), and Ghanaian (64·6%; aHR=6·00; 95%CI=4·33–8·30) origin. Compared to those of Dutch origin, differences in incidence became wider during the second versus first wave for all ethnic minority groups (all p-values for interaction
- Published
- 2022
- Full Text
- View/download PDF
3. SARS-CoV-2 antibody prevalence and correlates of six ethnic groups living in Amsterdam, the Netherlands: a population-based cross-sectional study, June–October 2020
- Author
-
Karien Stronks, Charles Agyemang, Aeilko H Zwinderman, Maria Prins, Liza Coyer, Anders Boyd, Anja Lok, Bert-Jan H van den Born, Henrike Galenkamp, Eric P Moll van Charante, Tjalling Leenstra, Janke Schinkel, Anitra D M Koopman, Arnoud Verhoeff, Suzanne Jurriaans, and Lonneke A van Vught
- Subjects
Medicine - Published
- 2022
- Full Text
- View/download PDF
4. Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathwayResearch in context
- Author
-
Thijs van Montfort, Renée van der Sluis, Gilles Darcis, Doyle Beaty, Kevin Groen, Alexander O. Pasternak, Georgios Pollakis, Monique Vink, Ellen M. Westerhout, Mohamed Hamdi, Margreet Bakker, Boas van der Putten, Suzanne Jurriaans, Jan H. Prins, Rienk Jeeninga, Adri A.M. Thomas, Dave Speijer, and Ben Berkhout
- Subjects
Medicine ,Medicine (General) ,R5-920 - Abstract
Background: The latent HIV-1 reservoir in treated patients primarily consists of resting memory CD4+ T cells. Stimulating the T-cell receptor (TCR), which facilitates transition of resting into effector T cells, is the most effective strategy to purge these latently infected cells. Here we supply evidence that TCR-stimulated effector T cells still frequently harbor latent HIV-1. Methods: Primary HIV-1 infected cells were used in a latency assay with or without dendritic cells (DCs) and reversion of HIV-1 latency was determined, in the presence or absence of specific pathway inhibitors. Findings: Renewed TCR-stimulation or subsequent activation with latency reversing agents (LRAs) did not overcome latency. However, interaction of infected effector cells with DCs triggered further activation of latent HIV-1. When compared to TCR-stimulation only, CD4+ T cells from aviremic patients receiving TCR + DC-stimulation reversed latency more frequently. Such a “one-two punch” strategy seems ideal for purging the reservoir. We determined that DC contact activates the PI3K-Akt-mTOR pathway in CD4+ T cells. Interpretation: This insight could facilitate the development of a novel class of potent LRAs that purge latent HIV beyond levels reached by T-cell activation. Keywords: Dendritic cells, Latency, PI3K, Akt, mTOR, Activated T cells
- Published
- 2019
- Full Text
- View/download PDF
5. CD32+CD4+ T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency
- Author
-
Gilles Darcis, Neeltje A. Kootstra, Berend Hooibrink, Thijs van Montfort, Irma Maurer, Kevin Groen, Suzanne Jurriaans, Margreet Bakker, Carine van Lint, Ben Berkhout, and Alexander O. Pasternak
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Summary: The HIV latent reservoir forms the major hurdle to an HIV cure. The discovery of CD32 as marker of this reservoir has aroused much interest, but subsequent reports have challenged this finding. Here, we observe a positive correlation between the percentages of CD32+ cells among CD4+ T cells of aviremic cART-treated, HIV-infected individuals and their HIV DNA loads in peripheral blood. Moreover, optimization of the CD32+CD4+ T cell purification protocol reveals prominent enrichment for HIV DNA (mean, 292-fold) in these cells. However, no enrichment for HIV RNA is observed in CD32+CD4+ cells, yielding significantly reduced HIV RNA/DNA ratios. Furthermore, HIV proviruses in CD32+CD4+ cells can be reactivated ex vivo to produce virus, strongly suggesting that these cells support HIV transcriptional latency. Our results underscore the importance of isolating pure, bona fide CD32+CD4+ T cells for future studies and indicate that CD32 remains a promising candidate marker of the HIV reservoir. : CD32a was recently proposed to mark the HIV reservoir, but this finding was subsequently challenged. By using a sequential cell-sorting protocol to purify bona fide CD32+CD4+ cells, Darcis et al. demonstrate HIV DNA enrichment and ex vivo reactivation-mediated virus production in these cells, reinforcing CD32 as an HIV reservoir marker. Keywords: HIV reservoir, HIV latency, HIV cure, biomarker, HIV persistence, antiretroviral therapy, CD32
- Published
- 2020
- Full Text
- View/download PDF
6. Performance of VIDISCA-454 in Feces-Suspensions and Serum
- Author
-
Lia van der Hoek, Silvia D. Olabarriaga, Angela C. Luyf, Barbera D. C. van Schaik, Suzanne Jurriaans, Margreet Bakker, Richard Molenkamp, Sylvie M. Koekkoek, Marta Canuti, Bas B. Oude Munnink, Martin Deijs, Antoine H. C. van Kampen, and Michel de Vries
- Subjects
virus discovery ,VIDISCA ,diarrhoea ,HIV-1 ,norovirus ,Microbiology ,QR1-502 - Abstract
Virus discovery combining sequence unbiased amplification with next generation sequencing is now state-of-the-art. We have previously determined that the performance of the unbiased amplification technique which is operational at our institute, VIDISCA-454, is efficient when respiratory samples are used as input. The performance of the assay is, however, not known for other clinical materials like blood or stool samples. Here, we investigated the sensitivity of VIDISCA-454 with feces-suspensions and serum samples that are positive and that have been quantified for norovirus and human immunodeficiency virus type 1, respectively. The performance of VIDISCA-454 in serum samples was equal to its performance in respiratory material, with an estimated lower threshold of 1,000 viral genome copies. The estimated threshold in feces-suspension is around 200,000 viral genome copies. The decreased sensitivity in feces suspension is mainly due to sequences that share no recognizable identity with known sequences. Most likely these sequences originate from bacteria and phages which are not completely sequenced.
- Published
- 2012
- Full Text
- View/download PDF
7. Twelve-Month Antiretroviral Therapy Suppresses Plasma and Genital Viral Loads but Fails to Alter Genital Levels of Cytokines, in a Cohort of HIV-Infected Rwandan Women.
- Author
-
Pascale Ondoa, Raju Gautam, John Rusine, Rene Lutter, Suzanne Jurriaans, Neeltje Kootstra, Etienne Karita, and Janneke van de Wijgert
- Subjects
Medicine ,Science - Abstract
BackgroundGenital viral load (GVL) is the main determinant of sexual transmission of human immune-deficiency virus (HIV). The effect of antiretroviral therapy (ART) on local cervico-vaginal immunological factors associated with GVL is poorly described. We aimed to identify the risk factors of detectable GVL, and the impact of ART on HIV genital shedding and its correlates in a cohort of HIV-infected women, attending HIV care in Kigali, Rwanda.Materials and methodsAll participants were evaluated for GVL, plasma viral load (PVL), CD4 count, various sexually-transmitted infections (STIs) at baseline and at month 12. Genital concentration of 19 cytokines and mRNA expression of APOBEC3G and BST2, two host HIV restriction factors, were evaluated at baseline in all participants. Cytokine levels were re-assessed at month 12 only in participants eligible for ART at baseline. Risk factors of GVL ≥ 40 copies/mL at baseline and month 12 were assessed using logistic regression. Effect of 12-month ART on various local and systemic immunological parameters was examined using a paired t-test and McNemar as appropriate.Results96 of the 247 women enrolled in the study were eligible for ART. After 12 months of ART, PVL and GVL decreased to undetectable level in respectively 74 and 88% of treated participants. ART did not affect cytokine levels. HIV genital shedding occurred only when PVL was detectable. At baseline, GVL was independently associated with IL-1β after controlling for PVL, age and N. gonorrhea infection (95% CI 1.32-2.15) and at month 12 with MIP-1β (95% CI 0.96-21.32) after controlling for baseline GVL, PVL and month 12 IL-8.ConclusionSuppressive ART does not necessarily reduce genital level of immune activation. Minimizing all conditions favoring genital inflammation, including active detection and treatment of STIs, might reduce the risk of HIV transmission as supplement to the provision of potent ART.
- Published
- 2015
- Full Text
- View/download PDF
8. Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatment.
- Author
-
Marlous L Grijsen, Ferdinand W N M Wit, Suzanne Jurriaans, Frank P Kroon, Emile F Schippers, Peter Koopmans, Luuk Gras, Joep M A Lange, Jan M Prins, and Primo-SHM Study Group
- Subjects
Medicine ,Science - Abstract
Temporary cART during primary HIV-infection (PHI) did not select for drug resistance mutations after treatment interruption and did not affect the subsequent virological response to long-term cART. Our data demonstrate that fear of drug resistance development is not a valid argument to refrain from temporary early treatment during PHI.
- Published
- 2014
- Full Text
- View/download PDF
9. Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda.
- Author
-
John Rusine, Brenda Asiimwe-Kateera, Janneke van de Wijgert, Kimberly Rachel Boer, Enatha Mukantwali, Etienne Karita, Agnes Gasengayire, Suzanne Jurriaans, Menno de Jong, and Pascale Ondoa
- Subjects
Medicine ,Science - Abstract
Treatment outcomes of HIV patients receiving antiretroviral therapy (ART) in Rwanda are scarcely documented. HIV viral load (VL) and HIV drug-resistance (HIVDR) outcomes at month 12 were determined in a prospective cohort study of antiretroviral-naïve HIV patients initiating first-line therapy in Kigali. Treatment response was monitored clinically and by regular CD4 counts and targeted HIV viral load (VL) to confirm drug failure. VL measurements and HIVDR genotyping were performed retrospectively on baseline and month 12 samples. One hundred and fifty-eight participants who completed their month 12 follow-up visit had VL data available at month 12. Most of them (88%) were virologically suppressed (VL≤1000 copies/mL) but 18 had virological failure (11%), which is in the range of WHO-suggested targets for HIVDR prevention. If only CD4 criteria had been used to classify treatment response, 26% of the participants would have been misclassified as treatment failure. Pre-therapy HIVDR was documented in 4 of 109 participants (3.6%) with an HIVDR genotyping results at baseline. Eight of 12 participants (66.7%) with virological failure and HIVDR genotyping results at month 12 were found to harbor mutation(s), mostly NNRTI resistance mutations, whereas 4 patients had no HIVDR mutations. Almost half (44%) of the participants initiated ART at CD4 count ≤200 cell/µl and severe CD4 depletion at baseline (
- Published
- 2013
- Full Text
- View/download PDF
10. Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM?
- Author
-
Luuk Gras, Ronald B Geskus, Suzanne Jurriaans, Margreet Bakker, Ard van Sighem, Daniela Bezemer, Christophe Fraser, Jan M Prins, Ben Berkhout, Frank de Wolf, and ATHENA National Observational Cohort
- Subjects
Medicine ,Science - Abstract
Studies suggest that the HIV-1 epidemic in the Netherlands may have become more virulent, leading to faster disease progression if untreated. Analysis of CD4 cell count decline before antiretroviral therapy (ART) initiation, a surrogate marker for disease progression, may be hampered by informative censoring as ART initiation is more likely with a steeper CD4 cell count decline.Development of CD4 cell count from 9 to 48 months after seroconversion was analyzed using a mixed-effects model and 2 models that jointly modeled CD4 cell counts and time to censoring event (start ART,
- Published
- 2013
- Full Text
- View/download PDF
11. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.
- Author
-
Marlous L Grijsen, Radjin Steingrover, Ferdinand W N M Wit, Suzanne Jurriaans, Annelies Verbon, Kees Brinkman, Marchina E van der Ende, Robin Soetekouw, Frank de Wolf, Joep M A Lange, Hanneke Schuitemaker, Jan M Prins, and Primo-SHM Study Group
- Subjects
Medicine - Abstract
BackgroundThe objective of this study was to assess the benefit of temporary combination antiretroviral therapy (cART) during primary HIV infection (PHI).Methods and findingsAdult patients with laboratory evidence of PHI were recruited in 13 HIV treatment centers in the Netherlands and randomly assigned to receive no treatment or 24 or 60 wk of cART (allocation in a 1∶1∶1 ratio); if therapy was clinically indicated, participants were randomized over the two treatment arms (allocation in a 1∶1 ratio). Primary end points were (1) viral set point, defined as the plasma viral load 36 wk after randomization in the no treatment arm and 36 wk after treatment interruption in the treatment arms, and (2) the total time that patients were off therapy, defined as the time between randomization and start of cART in the no treatment arm, and the time between treatment interruption and restart of cART in the treatment arms. cART was (re)started in case of confirmed CD4 cell count < 350 cells/mm(3) or symptomatic HIV disease. In total, 173 participants were randomized. The modified intention-to-treat analysis comprised 168 patients: 115 were randomized over the three study arms, and 53 randomized over the two treatment arms. Of the 115 patients randomized over the three study arms, mean viral set point was 4.8 (standard deviation 0.6) log(10) copies/ml in the no treatment arm, and 4.0 (1.0) and 4.3 (0.9) log(10) copies/ml in the 24- and 60-wk treatment arms (between groups: p < 0.001). The median total time off therapy in the no treatment arm was 0.7 (95% CI 0.0-1.8) y compared to 3.0 (1.9-4.2) and 1.8 (0.5-3.0) y in the 24- and 60-wk treatment arms (log rank test, p < 0.001). In the adjusted Cox analysis, both 24 wk (hazard ratio 0.42 [95% CI 0.25-0.73]) and 60 wk of early treatment (hazard ratio 0.55 [0.32-0.95]) were associated with time to (re)start of cART.ConclusionsIn this trial, temporary cART during PHI was found to transiently lower the viral set point and defer the restart of cART during chronic HIV infection.
- Published
- 2012
- Full Text
- View/download PDF
12. Molecular and phylogeographic analysis of human immuno-deficiency virus type 1 strains infecting treatment-naive patients from Kigali, Rwanda.
- Author
-
John Rusine, Suzanne Jurriaans, Janneke van de Wijgert, Marion Cornelissen, Brenda Kateera, Kimberly Boer, Etienne Karita, Odette Mukabayire, Menno de Jong, and Pascale Ondoa
- Subjects
Medicine ,Science - Abstract
This study aimed at describing the genetic subtype distribution of HIV-1 strains circulating in Kigali and their epidemiological link with the HIV-1 strains from the five countries surrounding Rwanda. One hundred and thirty eight pol (RT and PR) sequences from 116 chronically- and 22 recently-infected antiretroviral therapy (ART)-naïve patients from Kigali were generated and subjected to HIV drug resistance (HIV-DR), phylogenetic and recombinant analyses in connection with 366 reference pol sequences from Rwanda, Burundi, Kenya, Democratic Republic of Congo, Tanzania and Uganda (Los Alamos database). Among the Rwandan samples, subtype A1 predominated (71.7%), followed by A1/C recombinants (18.1%), subtype C (5.8%), subtype D (2.9%), one A1/D recombinant (0.7%) and one unknown subtype (0.7%). Thirteen unique and three multiple A1/C recombinant forms were identified. No evidence for direct transmission events was found within the Rwandan strains. Molecular characteristics of HIV-1 were similar between chronically and recently-infected individuals and were not significantly associated with demographic or social factors. Our report suggests that the HIV-1 epidemic in Kigali is characterized by the emergence of A1/C recombinants and is not phylogenetically connected with the HIV-1 epidemic in the five neighboring countries. The relatively low level of transmitted HIV-DR mutations (2.9%) reported here indicates the good performance of the ART programme in Rwanda. However, the importance of promoting couples' counseling, testing and disclosure during HIV prevention strategies is highlighted.
- Published
- 2012
- Full Text
- View/download PDF
13. Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands.
- Author
-
Marion Cornelissen, Fokla Zorgdrager, Petra Blom, Suzanne Jurriaans, Sjoerd Repping, Elisabeth van Leeuwen, Margreet Bakker, Ben Berkhout, and Antoinette C van der Kuyl
- Subjects
Medicine ,Science - Abstract
BackgroundXenotropic murine leukaemia virus-related virus (XMRV) is a recently discovered human gammaretrovirus with yet unknown prevalence and transmission route(s). Its presence in prostate stromal fibroblasts and prostatic secretions suggests that XMRV might be sexually transmitted. We chose to study a compartment closely connected to the prostate, a location where XMRV was detected in independent studies. Seminal plasma samples from HIV-1 infected men were examined as they have an increased probability of acquiring sexually transmitted pathogens.Methodology/principal findingsWe studied the prevalence of XMRV in 93 seminal plasma samples of 54 HIV-1 infected men living in The Netherlands with a nested PCR amplification specifically targeting the XMRV gag gene. As a control for the presence and integrity of retrovirus particles, HIV-1 was amplified from the same samples with a PCR amplification targeting the env gene of the virus, or HIV-1 was quantified with a real-time PCR amplifying part of the pol gene.Conclusions/significanceAlthough HIV-1 was amplified from 25% of the seminal plasma samples, no XMRV was detected, suggesting that either the prevalence of XMRV is very low in The Netherlands, or that XMRV is not naturally present in the seminal plasma.
- Published
- 2010
- Full Text
- View/download PDF
14. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.
- Author
-
Alexander O Pasternak, Suzanne Jurriaans, Margreet Bakker, Jan M Prins, Ben Berkhout, and Vladimir V Lukashov
- Subjects
Medicine ,Science - Abstract
BACKGROUND:Combination antiretroviral therapy (cART), the standard of care for HIV-1 infection, is considered to be successful when plasma viremia remains below the detection limit of commercial assays. Yet, cART fails in a substantial proportion of patients after the apparent success. No laboratory markers are known that are predictive of cART outcome in initial responders during the period of undetectable plasma viremia. METHODOLOGY/PRINCIPAL FINDINGS:Here, we report the results of a retrospective longitudinal study of twenty-six HIV-infected individuals who initially responded to cART by having plasma viremia suppressed to
- Published
- 2009
- Full Text
- View/download PDF
15. Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands.
- Author
-
Luuk Gras, Suzanne Jurriaans, Margreet Bakker, Ard van Sighem, Daniela Bezemer, Christophe Fraser, Joep Lange, Jan M Prins, Ben Berkhout, Frank de Wolf, and ATHENA National Observational Cohort Study
- Subjects
Medicine ,Science - Abstract
HIV-1 RNA plasma concentration at viral set-point is associated not only with disease outcome but also with the transmission dynamics of HIV-1. We investigated whether plasma HIV-1 RNA concentration and CD4 cell count at viral set-point have changed over time in the HIV epidemic in the Netherlands.We selected 906 therapy-naïve patients with at least one plasma HIV-1 RNA concentration measured 9 to 27 months after estimated seroconversion. Changes in HIV-1 RNA and CD4 cell count at viral set-point over time were analysed using linear regression models. The ATHENA national observational cohort contributed all patients who seroconverted in or after 1996; the Amsterdam Cohort Studies (ACS) contributed seroconverters before 1996. The mean of the first HIV-1 RNA concentration measured 9-27 months after seroconversion was 4.30 log(10) copies/ml (95% CI 4.17-4.42) for seroconverters from 1984 through 1995 (n = 163); 4.27 (4.16-4.37) for seroconverters 1996-2002 (n = 232), and 4.59 (4.52-4.66) for seroconverters 2003-2007 (n = 511). Compared to patients seroconverting between 2003-2007, the adjusted mean HIV-1 RNA concentration at set-point was 0.28 log(10) copies/ml (95% CI 0.16-0.40; p
- Published
- 2009
- Full Text
- View/download PDF
16. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users.
- Author
-
Charlotte van den Berg, Colette Smit, Margreet Bakker, Ronald Geskus, Ben Berkhout, Suzanne Jurriaans, Roel Coutinho, Katja Wolthers, and Maria Prins
- Subjects
HEPATITIS C ,DRUG abuse ,HIV ,REGRESSION analysis - Abstract
Abstract Injecting drug users (DU) are at high risk for hepatitis C virus (HCV) and HIV infections. To examine the prevalence and incidence of these infections over a 20-year period (1985–2005), the authors evaluated 1276 DU from the Amsterdam Cohort Studies who had been tested prospectively for HIV infection and retrospectively for HCV infection. To compare HCV and HIV incidences, a smooth trend was assumed for both curves over calendar time. Risk factors for HCV seroconversion were determined using Poisson regression. Among ever-injecting DU, the prevalence of HCV antibodies was 84.5% at study entry, and 30.9% were co-infected with HIV. Their yearly HCV incidence dropped from 27.5/100 person years (PY) in the 1980s to 2/100 PY in recent years. In multivariate analyses, ever-injecting DU who currently injected and borrowed needles were at increased risk of HCV seroconversion (incidence rate ratio 29.9, 95% CI 12.6, 70.9) compared to ever-injecting DU who did not currently inject. The risk of HCV seroconversion decreased over calendar time. The HCV incidence in ever-injecting DU was on average 4.4 times the HIV incidence, a pattern seen over the entire study period. The simultaneous decline of both HCV and HIV incidence probably results from reduced risk behavior at the population level. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
17. Characterization of An HIV-1 Group M Variant That Is Distinct from The Known Subtypes.
- Author
-
Lia Van Der Hoek, Georgios Pollakis, Vladimir V. Lukashov, Maarten F. Jebbink, Rienk E. Jeeninga, Margreet Bakker, Nicole Dukers, Suzanne Jurriaans, William A. Paxton, Nicole K.T. Back, and Ben Berkhout
- Abstract
We identified an HIV-1 variant that belongs to the M group, with limited similarity of short genetic regions (100–200 nt) to subtype K, but the remainder of the genome is unrelated to any established HIV-1 subtype. The isolate was obtained from an HIV-1-positive male, living in the Netherlands, who encountered the virus before 1989, most probably via heterosexual contact in Africa. We describe the full-length genome sequence of four biological clones that were obtained from two samples collected 5 years apart. At both time points all open reading frames were intact. Within the 5-year interval, the person received antiretroviral therapy with zalcitabine and zidovudine for almost 4 years. Evolution of drug-resistant variants is likely given the increase in viral RNA load to ±10,000 copiesml during the last year of treatment. Surprisingly, the only regular RT mutation acquired during this period was K70R, which suggests that the genetic background of this variant is perhaps not suitable for the generation of the standard 41L, 67N, and 215YF mutations that typically arise during prolonged, nonsuccessful, zidovudine treatment. Awaiting the discovery of at least two additional, epidemiologically unrelated patients with a phylogenetically related HIV-1 variant, we can designate this variant a new HIV-1 subtype, or a distinct branch of subtype K. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
18. Antiviral Activity of HIV Type 1 Protease Inhibitors Nelfinavir and Indinavir in VivoIs Not Influenced by P-Glycoprotein Activity on CD4T Cells.
- Author
-
Sanjay U.C. Sankatsing, Marion Cornelissen, Nico Kloosterboer, Kristel M.L. Crommentuyn, Tessa M. Bosch, Frederik P. Mul, Suzanne Jurriaans, Alwin D.R. Huitema, Jos H. Beijnen, Joep M.A. Lange, Jan M. Prins, and Hanneke Schuitemaker
- Abstract
P-glycoprotein (P-gp) can compromise the antiretroviral effect of a protease inhibitor (PI)-containing regimen for HIV-1, but can also reduce HIV-1 replication. We studied the net effect of P-gp on the intracellular HIV-1 RNA and DNA load in vivo. CD4T cells were isolated from 27 HIV-1 patients (13 without and 14 with a PI-containing regimen) and subsequently sorted in CD45RO−(naive) and CD45RO(memory) subsets with either high (P-gphigh) or low (P-gplow) P-gp activity. Unspliced HIV-1 RNA and HIV-1 DNA load were determined. For each patient P-gphighand P-gplowsubsets were compared. In patients on a PI-containing regimen, intracellular unspliced HIV-1 RNA was significantly lower in P-gphigh-naive CD4cells compared to P-gplow-naive CD4cells (p 0.04). The same trend was seen in naive CD4cells of treatmentnaive patients. In both treated and untreated patients HIV-1 DNA levels were significantly lower in P-gphighthan in P-gplowmemory CD4cells (p 0.02 and p 0.04). High cellular P-gp activity coincided with a reduced intracellular HIV-1 load in vivo, both in therapy-naive and in PI-treated patients. Therefore we conclude that the potential efflux function of P-gp on PIs may be clinically less relevant than the effect of P-gp on intracellular HIV-1 replication. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
19. Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions.
- Author
-
Christine A Jansen, Iris M De Cuyper, Radjin Steingrover, Suzanne Jurriaans, Sanjay U Sankatsing, Jan M Prins, Joep M Lange, Debbie van Baarle, and Frank Miedema
- Published
- 2005
- Full Text
- View/download PDF
20. Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27- T cells in HIV-1-infected children.
- Author
-
Vincent Bekker, Corine Bronke, Henritte J Scherpbier, Jan F Weel, Suzanne Jurriaans, Pauline M Wertheim-van Dillen, Frank v Leth, Joep M Lange, Kiki Tesselaar, Debbie v Baarle, and Taco W Kuijpers
- Published
- 2005
- Full Text
- View/download PDF
21. HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil.
- Author
-
Suzanne Jurriaans
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.